《新股表現》康方生物(09926.HK)暗盤收23.8元 高上市價47%每手賺7,620元
根據輝立交易平台顯示,明天掛牌的康方生物-B(09926.HK)暗盤高開近30%報21元,最高見24.25元,收報23.8元,較上市價16.18元,高47.1%或7.62元;成交1,550萬股,涉資3.65億元。不計手續費,每手1,000股賬面賺7,620元。
康方是一家臨床階段生物製藥公司,致力於自主發現、開發及商業化首創及同類最佳療法,公司專注於滿足腫瘤、免疫及其他治療領域在全球未決醫療需求。是次上市共發售1.59億股,並已引入包括富達投資、Lake Bleu Prime Healthcare Master Funds、奧博資本、Boyu Capital Opportunities Master Fund、Hudson Bay Master Fund及國企結構調整基金等9名基石投資者,合共認購7,867.2萬股,其中前兩者認購所佔份額最大,分別認購3,137.3萬股及2,172萬股;10%公開發售獲638.2倍超購,凍資逾1,666億元,成為今年新股「凍資王」,已啟動回撥機制佔比增至50%,認購一手中籤率僅12%;股份以招股範圍(14.88-16.18元)上限定價,料集資淨額24.37億元,主要用作產品研發和商業化、以及在中國廣州及中山發展生產及研發設施等。上市聯席保薦人分別為大摩及摩通。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.